EC
PVLA

EcoR1 Capital’s Palvella Therapeutics PVLA Stock Holding History

EcoR1 Capital’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,302
Closed -$602K – 70
2020
Q1 		$602K Sell
3,302
-28,388
-90% -$7.15M 0.06% 48
2019
Q4 		$9.18M Buy
+31,690
New +$8.79M 0.83% 26

Other funds holding PVLA

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital's PVLA Position: Q2 2020 in Review

EcoR1 Capital sold out of Palvella Therapeutics (PVLA) in Q2 2020, closing a stake of 3,302 shares — an estimated $602K sold.

EcoR1 Capital first reported a position in PVLA in Q4 2019 and held it in 2 quarters. The position peaked at $9.18M in Q4 2019. 96 funds tracked by Wall St. Rank hold PVLA as of Q2 2020.

  • EcoR1 Capital reported no remaining Palvella Therapeutics position as of Q2 2020 after selling out during the quarter.
  • EcoR1 Capital sold 3,302 Palvella Therapeutics shares in Q2 2020, an estimated $602K.
  • EcoR1 Capital first reported a position in Palvella Therapeutics in Q4 2019 and held it in 2 quarters.
  • EcoR1 Capital's Palvella Therapeutics position peaked at $9.18M in Q4 2019.
  • 96 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2020.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.